Literature DB >> 25794564

[MUV researcher of the month, March 2015].

Martin Bauer1.   

Abstract

Mesh：

Year:  2015        PMID： 25794564     DOI： 10.1007/s00508-015-0778-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  10 in total

1.  Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.

Authors:  M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer
Journal:  Clin Pharmacol Ther       Date:  2011-12-14       Impact factor: 6.875

2.  Blood-brain barrier P-glycoprotein function in Alzheimer's disease.

Authors:  Daniëlle M E van Assema; Mark Lubberink; Martin Bauer; Wiesje M van der Flier; Robert C Schuit; Albert D Windhorst; Emile F I Comans; Nikie J Hoetjes; Nelleke Tolboom; Oliver Langer; Markus Müller; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Brain       Date:  2011-11-26       Impact factor: 13.501

3.  A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.

Authors:  Martin Bauer; Oliver Langer; Peter Dal-Bianco; Rudolf Karch; Martin Brunner; Aiman Abrahim; Rupert Lanzenberger; Andrea Hofmann; Christian Joukhadar; Paolo Carminati; Orlando Ghirardi; Paola Piovesan; Gianluigi Forloni; Mario E Corrado; Nadège Lods; Robert Dudczak; Eduard Auff; Kurt Kletter; Markus Müller
Journal:  Clin Pharmacol Ther       Date:  2006-09       Impact factor: 6.875

4.  Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.

Authors:  Martin Bauer; Rudolf Karch; Friederike Neumann; Claudia C Wagner; Kurt Kletter; Markus Müller; Wolfgang Löscher; Markus Zeitlinger; Oliver Langer
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-16       Impact factor: 6.200

5.  Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET.

Authors:  Martin Bauer; Rudolf Karch; Friederike Neumann; Aiman Abrahim; Claudia C Wagner; Kurt Kletter; Markus Müller; Markus Zeitlinger; Oliver Langer
Journal:  Eur J Clin Pharmacol       Date:  2009-08-05       Impact factor: 2.953

6.  A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.

Authors:  Claudia C Wagner; Martin Bauer; Rudolf Karch; Thomas Feurstein; Stephan Kopp; Peter Chiba; Kurt Kletter; Wolfgang Löscher; Markus Müller; Markus Zeitlinger; Oliver Langer
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

7.  P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.

Authors:  Maria Feldmann; Marie-Claude Asselin; Joan Liu; Shaonan Wang; Adam McMahon; José Anton-Rodriguez; Matthew Walker; Mark Symms; Gavin Brown; Rainer Hinz; Julian Matthews; Martin Bauer; Oliver Langer; Maria Thom; Terry Jones; Christian Vollmar; John S Duncan; Sanjay M Sisodiya; Matthias J Koepp
Journal:  Lancet Neurol       Date:  2013-06-18       Impact factor: 44.182

8.  Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.

Authors:  Martin Bauer; Rudolf Karch; Markus Zeitlinger; Johann Stanek; Cécile Philippe; Wolfgang Wadsak; Markus Mitterhauser; Walter Jäger; Helmuth Haslacher; Markus Müller; Oliver Langer
Journal:  J Nucl Med       Date:  2013-07-05       Impact factor: 10.057

9.  In vivo P-glycoprotein function before and after epilepsy surgery.

Authors:  Martin Bauer; Rudolf Karch; Markus Zeitlinger; Joan Liu; Matthias J Koepp; Marie-Claude Asselin; Sanjay M Sisodiya; Johannes A Hainfellner; Wolfgang Wadsak; Markus Mitterhauser; Markus Müller; Ekaterina Pataraia; Oliver Langer
Journal:  Neurology       Date:  2014-09-03       Impact factor: 9.910

10.  Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil.

Authors:  Oliver Langer; Martin Bauer; Alexander Hammers; Rudolf Karch; Ekaterina Pataraia; Matthias J Koepp; Aiman Abrahim; Gert Luurtsema; Martin Brunner; Raute Sunder-Plassmann; Friedrich Zimprich; Christian Joukhadar; Stephan Gentzsch; Robert Dudczak; Kurt Kletter; Markus Müller; Christoph Baumgartner
Journal:  Epilepsia       Date:  2007-05-01       Impact factor: 5.864
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.